Author/Editor		Cardoso, F; Bedard, PL; Winer, EP; Pagani, O; Senkus-Konefka, E; Fallowfield, LJ; Kyriakides, S; Costa, A; Čufer, T; Albain, KS
Title		International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
Type		članek
Source		J Natl Cancer Inst
Vol. and No.		Letnik 101, št. 17
Publication year		2009
Volume		str. 1174-81
Language		eng
Abstract		Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy.
Descriptors		BREAST NEOPLASMS ANTINEOPLASTIC AGENTS NEOPLASM STAGING NEOPLASM METASTASIS PRACTICE GUIDELINES